Skip to main content
Industry News
Sodium benzoate may not benefit patients with dementia

People with behavioral and psychological symptoms of dementia who received an average of 622 mg of sodium benzoate daily had similar primary and secondary outcomes, as well as similar safety results, compared with those who were given placebo, Taiwanese researchers reported in the Journal of Psychopharmacology. The findings prompted researchers to conclude that longer and higher-dose clinical trials are needed to gauge sodium benzoate's efficacy and safety for behavioral and psychological symptoms of dementia.

Full Story: